![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Highest Development Status: Undisclosed
Therapeutic Area: Endocrinology
Interventions: Exenatide,Insulin
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist||Gluc...
Trial ID: NA
Location: NA
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Oral
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.
Highest Development Status: Undisclosed
Therapeutic Area: Nutrition and Weight Loss
Interventions: Leptin
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Leptin receptor agonist
Trial ID: NA
Location: NA
Condition: Weight loss
Product Status: Undisclosed
Dosage Form: Capsule
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
Product Description: Leptin is a hormone predominantly made by adipose cells and enterocytes in the small intestine that helps to regulate energy balance by inhibiting hunger, which in turn diminishes fat storage in adipocytes.
PharmaCompass >>